Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01303133 · ClinicalTrials.gov registry record
Natural History of Amyloid Deposition in Adults With Down Syndrome
A clinical trial, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 81
- Enrollment target
NCT01303133: Completed study, sponsored by University of Pittsburgh.
NCT01303133 is a clinical trial that has completed, run by University of Pittsburgh. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01303133 has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the presence of amyloid in non-demented/functionally stable adults with DS as a function of age, dividing the sample into amyloid-positive and amyloid-negative groups. We will also obtain baseline cognitive measures across a range of areas that are often affected by AD.
Primary Outcome
Obtained via PiB PET scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2009-08 |
| Est. Completion | 2018-03-31 |
What the finished NCT01303133 record still lists
NCT01303133 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01303133 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01303133 about?
NCT01303133 is a clinical study titled "Natural History of Amyloid Deposition in Adults With Down Syndrome". The primary objective of this study is to assess the presence of amyloid in non-demented/functionally stable adults with DS as a function of age, dividing the sample into amyloid-positive and amyloid-negative groups. We will also obtain baseline cognitive measures across a range of areas that are of...
What is the current status of trial NCT01303133?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2009-08. Estimated completion is 2018-03-31.
Who is sponsoring clinical trial NCT01303133?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia